Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer

Trial Profile

Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Encapsulated cell therapy (Primary)
  • Indications Carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2017 Results from NCT01053013 and NCT00283075 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 10 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top